Observational studyUpdates in surgery2026
Laparoscopic surgery should be a viable option for T4 colon cancer: evidence from a propensity score matching analysis.
Observational study in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Laparoscopic surgery for T4 colon cancer: balancing oncological radicality and minimally invasive benefits.Updates in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe suitability of laparoscopy for T4 colon cancer (CC) remains controversial. This study aims to compare the short-term and long-term oncological outcomes specifically for T4 CC.
methodThis observational study included patients who underwent either laparoscopic resection (LR) or open resection (OR) for T4 CC (2015-2023). Propensity score matching (PSM) was used to balance covariates (age, sex, BMI, ASA classification and tumor staging). Primary outcomes were 3-year overall survival (OS) and disease-free survival (DFS). Secondary endpoints included postoperative outcomes and recurrence rates. Prognostic factors for OS and DFS were also analyzed and results of the logistic regression analyses were presented as hazard ratios (HR) with 95 confidence intervals (CI).
resultA total of 176 patients were enrolled, with 75 well-balanced pairs after PSM. The LR group demonstrated comparable major complication rates to the OR group (8.0% vs. 5.3%, P = 0.734). During a mean follow-up of 44.1 ± 28.1 months after LR versus 40.8 ± 23.6 months after OR (P = 0.960), postoperative recurrence rates were similar (LR: 24.0% vs. OR: 17.3%, P = 0.550). The 3-year OS rates were 76.8% and 81.9% in LR and OR respectively (P = 0.292), and 3-year DFS rates were 68.6% and 71.7% in LR and OR, respectively (P = 0.312). Multivariate cox regression analysis determined significant independent predictors for OS included age > 75 years (HR = 11.03, 95%CI 5.29-22.98, P < 0.001), adjuvant therapy (HR = 0.45, 95%CI 0.23-0.87, P = 0.017) and positive lymph nodes (HR = 1.12 per node, 95%CI 1.01-1.25, P = 0.035). Key determinants including age > 75 years (HR = 7.25, 95%CI 3.70-14.20, P < 0.001), adjuvant therapy (HR = 0.29, 95%CI 0.16-0.53, P < 0.001), AJCC staging (III vs. Ⅱ: HR = 2.56, 95%CI 1.07-6.12, P = 0.034) and excised lymph nodes (HR = 1.05 per node, 95%CI 1.02-1.07, P = 0.001) were indepently associated with DFS.
conclusionLR demonstrates comparable short-term and long-term oncological outcomes to OR and it should be considered as a safe and feasible option for T4 CC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.